Silver Book Fact

A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took alendronate. The study followed about 1,200 women with low bone mass for over a year.

Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate. http://www.rheumatology.org/press/2008/2008_press_14.asp. Published 2008

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • 30 drugs are currently in development for osteoporosis.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.